Dual biological treatments in immune-mediated disorders: a single center experience

Abstract Background Physicians may encounter situations where they need to co-administer omalizumab with non–IgE-targeting monoclonal antibodies. In this study, we share our experience with these dual biologic treatments. Objective To evaluate the efficacy and safety of dual biological therapy using...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Oded Shamriz, Elchanan Parnasa, Limor Rubin, Aviv Talmon, Yaarit Ribak, Isaam Hindi, Hagit Peleg, Ronit Confino-Cohen, Yuval Tal
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2025-04-01
Edice:	BMC Immunology
Témata:	Omalizumab Biologics Dual biologics IgE Biotherapy
On-line přístup:	https://doi.org/10.1186/s12865-025-00705-8
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!